辫丑辞蝉辫丑辞-肠-碍颈迟(罢测谤823)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 12915R
英文名称辫丑辞蝉辫丑辞-肠-碍颈迟(罢测谤823)
中文名称磷酸化原癌基因肠-办颈迟抗体
别 名c-Kit (phospho Y823); c-Kit (phospho Tyr823); p-c-Kit (Tyr 823); C Kit; c-Kit; CD 117; CD117; CD117 antigen; KIT; KIT_HUMAN; Mast/stem cell growth factor receptor; Mast/stem cell growth factor receptor Kit; p145 c-kit; PBT; Piebald trait protein; Proto oncogene c Kit; Proto oncogene tyrosine protein kinase Kit; Proto-oncogene c-Kit; SCF Receptor; SCFR; soluble KIT variant 1; Stem cell factor receptor; tyrosine protein kinase Kit; Tyrosine-protein kinase Kit; v kit Hardy Zuckerman 4 feline sarcoma viral oncogene homolog; v kit Hardy Zuckerman 4 feline sarcoma viral oncogene like protein; v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog.
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 信号转导 转录调节因子 激酶和磷酸酶 细胞膜受体
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
辫丑辞蝉辫丑辞-肠-碍颈迟(罢测谤823)抗体交叉反应 Human, Mouse, Rat, Dog, Pig, Cow, Horse, Sheep,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg/Test ICC=1:100-500 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量145kDa
细胞定位细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human c-Kit around the phosphorylation site of Tyr823:SN(p-Y)VV
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
辫丑辞蝉辫丑辞-肠-碍颈迟(罢测谤823)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
c-Kit is a transmembrane tyrosine kinase encoded by the cKit proto oncogene. c-Kit acts to regulate a variety of biological responses including cell proliferation, apoptosis, chemotaxis and adhesion. Ligand binding to the extracellular domain leads to autophosphorylation on several tyrosine residues within the cytoplasmic domain, and activation. Mutations in c-Kit have been found to be important for tumor growth and progression in a variety of cancers including mast cell diseases, gastrointestinal stromal tumor, acute myeloid leukemia, Ewing sarcoma and lung cancer. Phosphorylation at tyrosine 721 of c-Kit allows binding and activation of PI3 kinase.
Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1, SH2B2/APS and CBL. Activates the AKT1 signaling pathway by phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Activated KIT also transmits signals via GRB2 and activation of RAS, RAF1 and the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3, STAT5A and STAT5B. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate.
Subunit:
Monomer in the absence of bound KITLG/SCF. Homodimer in the presence of bound KITLG/SCF, forming a heterotetramer with two KITLG/SCF molecules. Interacts (via phosphorylated tyrosine residues) with the adapter proteins GRB2 and GRB7 (via SH2 domain), and SH2B2/APS. Interacts (via C-terminus) with MPDZ (via the tenth PDZ domain). Interacts (via phosphorylated tyrosine residues) with PIK3R1 and PIK3 catalytic subunit. Interacts (via phosphorylated tyrosine) with CRK (isoform Crk-II), FYN, SHC1 and MATK/CHK (via SH2 domain). Interacts with LYN and FES/FPS. Interacts (via phosphorylated tyrosine residues) with the protein phosphatases PTPN6/SHP-1 (via SH2 domain), PTPN11/SHP-2 (via SH2 domain) and PTPRU. Interacts with PLCG1. Interacts with DOK1 and TEC. Subcellular Location : Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Cell membrane; Single-pass type I membrane protein. Isoform 3: Cytoplasm. Note=Detected in the cytoplasm of spermatozoa, especially in the equatorial and subacrosomal region of the sperm head. Subcellular Location : Isoform 1: Cell membrane; Single-pass type I membrane protein. Isoform 2: Cell membrane; Single-pass type I membrane protein. Isoform 3: Cytoplasm.
Subcellular Location:
Cell membrane and Cytoplasm. Detected in the cytoplasm of spermatozoa, especially in the equatorial and subacrosomal region of the sperm head.
Tissue Specificity:
Isoform 1 and isoform 2 are detected in spermatogonia and Leydig cells. Isoform 3 is detected in round spermatids, elongating spermatids and spermatozoa (at protein level). Widely expressed. Detected in the hematopoietic system, the gastrointestinal system, in melanocytes and in germ cells.
Post-translational modifications:
Ubiquitinated by SOCS6. KIT is rapidly ubiquitinated after autophosphorylation induced by KITLG/SCF binding, leading to internalization and degradation. Autophosphorylated on tyrosine residues. KITLG/SCF binding enhances autophosphorylation. Isoform 1 shows low levels of tyrosine phosphorylation in the absence of added KITLG/SCF (in vitro). Kinase activity is down-regulated by phosphorylation on serine residues by protein kinase C family members.
Phosphorylation at Tyr-568 is required for interaction with PTPN11/SHP-2, CRK (isoform Crk-II) and members of the SRC tyrosine-protein kinase family. Phosphorylation at Tyr-570 is required for interaction with PTPN6/SHP-1. Phosphorylation at Tyr-703, Tyr-823 and Tyr-936 is important for interaction with GRB2. Phosphorylation at Tyr-721 is important for interaction with PIK3R1. Phosphorylation at Tyr-823 and Tyr-936 is important for interaction with GRB7.
DISEASE:
Defects in KIT are a cause of piebald trait (PBT) [MIM:172800]. PBT is an autosomal dominant genetic developmental abnormality of pigmentation characterized by congenital patches of white skin and hair that lack melanocytes. Defects in KIT are a cause of gastrointestinal stromal tumor (GIST) [MIM:606764]. Defects in KIT have been associated with testicular germ cell tumor (TGCT) [MIM:273300]. A common solid malignancy in males. Germ cell tumors of the testis constitute 95% of all testicular neoplasms.
Defects in KIT are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. Note=Somatic mutations that lead to constitutive activation of KIT are detected in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the kinase domain can result in a constitutively activated kinase.
Similarity:
Belongs to the protein kinase superfamily. Tyr protein kinase family.
CSF-1/PDGF receptor subfamily.
Contains 5 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. Database links : UniProtKB/Swiss-Prot: P10721.1
Gene ID:
3815
辫丑辞蝉辫丑辞-肠-碍颈迟(罢测谤823)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
辫丑辞蝉辫丑辞-肠-碍颈迟(罢测谤823)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 Caveolin-1 细胞质膜微囊蛋白-1抗体
合格 phospho-EIF2S1 (Ser49) 磷酸化真核启动因子2α抗体
合格 eIF4A3 eIF4A3蛋白抗体
合格 phospho-eIF4EBP1（Thr70） 磷酸化eIF4E结合蛋白抗体
合格 phospho-EIF4B (Ser406) 磷酸化真核翻译起始因子4B抗体
合格 ELMO3 ELMO3蛋白抗体
合格 ELMOD1 ELMOD1蛋白抗体
合格 Adenosine Receptor A2a 腺苷A2A受体抗体
合格 合格 ELOV3 ELOV3蛋白抗体
合格 ELSPBP1 附睾精子结合蛋白1抗体
合格 EMG1 EMG1蛋白抗体
合格 Emi1 早期有丝分裂抑制蛋白1抗体
合格 EMR3 EMR3蛋白抗体
合格 合格 合格 LIFR 白血病抑制因子受体抗体
合格 ENDOD1 核酸内切酶结构域蛋白1抗体
合格 ENOX2 ENOX2蛋白抗体
合格 合格 CD130 白细胞介素6受体β/CD130抗体
合格 IL-23R 白介素-23受体抗体
合格 EPM2AIP1 肌痉挛性癫痫病相互作用蛋白1抗体
合格 Epoxide hydrolase 1 环氧化物水解酶1抗体
合格 Eps8L3 EPS8相关蛋白3抗体
合格 ERGIC2 ERGIC2蛋白抗体
合格 Ermin Ermin蛋白抗体
合格 ERO1LB Ero1-Lβ蛋白抗体
合格 合格 ERp57 内质网蛋白57抗体
合格 ETS2.3 ETS2.3蛋白抗体
合格 Phospho-Estrogen Receptor alpha (Ser104) 磷酸化雌**受体α抗体
合格 合格 Phospho-Estrogen Receptor alpha (Ser106) 磷酸化雌**受体α抗体
合格 EVI5L EVI5L蛋白抗体
合格 EVPLL EVPLL蛋白抗体
合格 EVX2 EVX2蛋白抗体
合格 合格 EXD2 EXD2蛋白抗体